PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-12.38%
Both yoy net incomes decline, with AGEN at -30.66%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-27.15%
Negative yoy D&A while AGEN is 10.66%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-5631.45%
Negative yoy deferred tax while AGEN stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
0.93%
SBC growth while AGEN is negative at -4.36%. John Neff would see competitor possibly controlling share issuance more tightly.
-32.67%
Negative yoy working capital usage while AGEN is 90.31%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
107.56%
Lower AP growth vs. AGEN's 428.18%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-665.24%
Negative yoy usage while AGEN is 1730.80%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
5631.45%
Some yoy increase while AGEN is negative at -120.11%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-36.10%
Both yoy CFO lines are negative, with AGEN at -47.05%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
78.08%
CapEx growth well above AGEN's 8.74%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.08%
Investing outflow well above AGEN's 59.18%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
66.67%
We repay more while AGEN is negative at -245.71%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
210.14%
We slightly raise equity while AGEN is negative at -13.90%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.